Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologics in Refractory Vasculitis (BIOVAS)
NCT05168475Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jul 2021
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, infliximab, tocilizumab in giant cell arteritis (GCA), Takayasu arteritis (TAK), Cogan syndrome, relapsing polychondritis (RP), cryoglobulinemic vasculitis, sponsored by Cambridge University Hospitals NHS Foundation Trust. Started Jul 2021; status: terminated.
02
Drugs
rituximabinfliximabtocilizumab
03
Conditions
giant cell arteritis (GCA)Takayasu arteritis (TAK)Cogan syndromerelapsing polychondritis (RP)cryoglobulinemic vasculitis
Beyond the preview
Go deeper on NCT05168475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168475.